All articles by GlobalData Healthcare

Biopharma venture financing declines 20.2% YOY in Q1 2025 amid persistent investor caution

Biopharmaceutical drug company venture financing witnessed a downturn in Q1 2025, with $6.5bn raised—a 20.2% decline from the $8.1bn raised…
Impending US tariffs signal uncertain future for global pharma, says GlobalData

In early 2025, US President Donald Trump mentioned the possibility of potential tariffs on foreign-made pharmaceuticals. This threat was raised…
US tariffs likely to disrupt drug development costs and prices, says GlobalData

While the pharmaceutical industry is currently exempt from US tariffs, there is an increased risk to the stability of the…
Top 20 biopharmas’ market cap rises 6% in Q1 2025 amid tariff headwinds

The top 20 biopharmaceutical companies demonstrated a strong start to 2025, despite ongoing uncertainty surrounding the potential impact of President…
The 7MM atopic dermatitis market to experience growth, reaching $22.4bn by 2033

Atopic dermatitis (AD) is a widespread, chronic inflammatory skin condition that can affect patients of all ages and is the…

Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts?

Chimeric antigen receptor (CAR) T-cell therapies have drastically changed treatment paradigms in relapsed and refractory (R/R) haematological malignancies since the…
ESCMID Global 2025: Climate-informed infectious disease risk management

At the 35th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Vienna, Austria, the development of…
COPD market projected to grow to $30.2bn in the 7MM by 2033

The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and…
AAN 2025: Long-term outcome data on steroid regimens in MG may guide treatment standards

On 7 April, at the 2025 American Academy of Neurology (AAN) meeting, a poster presentation by the Peking Union Medical…
AD/PD 2025: Reporting of first real-world data for Leqembi focuses on operational challenges and safety

Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 International Conference…